Stevens-Johnson syndrome and toxic epidermal necrolysis reactions to BRAF and MEK inhibitors in patients with melanoma: A systematic review

J Am Acad Dermatol. 2021 Oct;85(4):981-983. doi: 10.1016/j.jaad.2020.09.027. Epub 2020 Sep 11.

Authors

Yuliya Lytvyn¹, Asfandyar Mufti², Muskaan Sachdeva¹, Khalad Maliyar¹, Jensen Yeung³

Affiliations

¹ Faculty of Medicine, University of Toronto, Ontario, Canada.
² Division of Dermatology, University of Toronto, Ontario, Canada.
³ Division of Dermatology, University of Toronto, Ontario, Canada. Electronic address: jensen.yeung@utoronto.ca.

PMID: 32926988
DOI: 10.1016/j.jaad.2020.09.027

No abstract available

Publication types

Letter
Systematic Review

MeSH terms

Humans
Melanoma* / drug therapy
Mitogen-Activated Protein Kinase Kinases
Proto-Oncogene Proteins B-raf / genetics
Stevens-Johnson Syndrome* / etiology

Substances

BRAF protein, human
Proto-Oncogene Proteins B-raf
Mitogen-Activated Protein Kinase Kinases